MarketCapExport financials
American Well Corporation (AMWL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
American Well Corporation Financial Ratios 2025-2011 | AMWL
Brief overview of American Well Corporation's valuation and returns
Current figures are compared with the company's own five-year history for 2021–2025.
The valuation comparison uses P/S 0.29x (median 0.29x), P/B 0.29x (median 0.29x). On average, multiples differ from their five-year medians by only 0%. Valuation is near its familiar historical range.
End-period return metrics are ROE -40.6%, ROA -29.6%, ROCE -44.7%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
The cash cycle lengthened by 16.7 days to 84.9 days. Operations require more funding.
Conclusion
American Well Corporation's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios American Well Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.7 | -0.8 | -0.0 | -0.2 | -6.1 | -10.8 | -0.1 | -0.2 | - | - | - | - | - | - | - |
P/S |
0.3 | 0.7 | 0.1 | 0.2 | 4.3 | 9.9 | 0.1 | 0.1 | - | - | - | - | - | - | - |
EPS |
-6.0 | -13.9 | -47.5 | -19.7 | -0.7 | -2.3 | -2.1 | -1.3 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
-34.6 M | 63.8 M | -244 M | -362 M | 513 M | 1.61 B | 652 M | 648 M | - | - | - | - | - | - | - |
EBITDA per Share |
-4.44 | -12.3 | -46.5 | -18.2 | -0.64 | -2.19 | -2.11 | -1.23 | - | - | - | - | - | - | - |
EV/EBITDA |
0.5 | -0.3 | 0.4 | 1.5 | -2.8 | -11.8 | 1.5 | 0.8 | - | - | - | - | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | - | - | 0.1 | 0.0 | 0.08 | - | - | - | - | - | - | - |
P/B |
0.3 | 0.5 | 0.0 | 0.0 | 0.9 | 1.9 | -0.0 | -0.0 | - | - | - | - | - | - | - |
P/CF |
-1.1 | -1.4 | -0.1 | -0.2 | -7.6 | -21.6 | -0.1 | -0.1 | - | - | - | - | - | - | - |
ROE % |
-40.62 | -68.29 | -145.44 | -25.42 | -13.99 | -18.01 | 31.04 | 25.77 | - | - | - | - | - | - | - |
ROA % |
-29.56 | -47.74 | -114.49 | -22.21 | -12.20 | -16.30 | -17.44 | -10.76 | - | - | - | - | - | - | - |
ROCE % |
-44.69 | -71.38 | -149.10 | -25.93 | -14.21 | -18.25 | -24.08 | -13.73 | - | - | - | - | - | - | - |
Current Ratio |
4.3 | 3.6 | 5.4 | 9.1 | 7.8 | 10.6 | 2.1 | 3.4 | - | - | - | - | - | - | - |
DSO |
89.0 | 90.4 | 79.3 | 72.3 | 69.8 | 33.7 | 80.3 | 98.6 | - | - | - | - | - | - | - |
DIO |
6.3 | 11.2 | 17.1 | 18.5 | 20.5 | 10.6 | 14.2 | 15.6 | - | - | - | - | - | - | - |
DPO |
10.4 | 11.6 | 13.4 | 22.1 | 22.1 | 6.7 | 29.7 | 26.3 | - | - | - | - | - | - | - |
Operating Cycle |
95.3 | 101.6 | 96.4 | 90.8 | 90.3 | 44.3 | 94.4 | 114.2 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
84.9 | 90.0 | 82.9 | 68.7 | 68.2 | 37.6 | 64.7 | 87.9 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios American Well Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.59 | -0.66 | - | -2 | -1.24 | -1.19 | - | -2.87 | -3.36 | -4.94 | -9.54 | -6.53 | -1.42 | - | -0.25 | -0.25 | -0.26 | - | -0.2 | -0.15 | -0.16 | - | -0.92 | -1.99 | -0.58 | - | -0.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.3 | -0.59 | - | -1.23 | -0.76 | -1.44 | - | -2.58 | -2.97 | -4.58 | -9.45 | -6.13 | -1.39 | - | -0.23 | -0.23 | -0.24 | - | -0.18 | -0.14 | -0.15 | - | -0.83 | -1.91 | -0.55 | - | -0.48 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-28.95 | -30.58 | -25.79 | -38.21 | -38.71 | -48.78 | -42.66 | -68.91 | -70.86 | -113.32 | -102.64 | -82.34 | -73.79 | -18.11 | -22.08 | -18.93 | -16.25 | -10.44 | -15.59 | -18.70 | -17.50 | -14.22 | -6.40 | 7.06 | 23.77 | 25.76 | 7.82 | 8.31 | 9.63 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-20.45 | -21.87 | -18.53 | -27.53 | -28.36 | -36.44 | -31.98 | -53.46 | -56.44 | -93.37 | -85.91 | -69.58 | -61.08 | -14.32 | -17.27 | -11.58 | -14.59 | -9.43 | -14.01 | -16.84 | -15.66 | -12.65 | -17.45 | -6.29 | -1.77 | - | -4.80 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-30.70 | -36.33 | -28.66 | -42.20 | -44.55 | -55.06 | -45.12 | -72.70 | -73.85 | -115.62 | -104.33 | -82.72 | -73.87 | -18.25 | -22.52 | -19.23 | -16.44 | -10.61 | -15.86 | -18.76 | -17.72 | -14.53 | -6.15 | -7.18 | -2.10 | - | 8.38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.5 | 3.8 | 4.3 | 3.9 | 4.1 | 3.7 | 3.6 | 3.6 | 3.9 | 4.4 | 5.5 | 6.0 | 6.2 | 9.1 | 9.7 | - | 8.9 | 7.8 | 8.0 | 13.0 | 12.4 | 10.6 | 10.6 | 10.6 | 10.6 | 4.0 | 4.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
96.2 | 88.8 | - | 88.5 | 80.8 | 98.2 | - | 123.6 | 113.9 | 97.7 | 70.1 | 76.2 | 81.4 | - | 30.1 | 33.3 | 70.0 | - | 55.3 | 55.5 | 65.7 | - | 66.1 | 60.3 | 66.3 | - | 43.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
3.9 | 4.0 | - | 6.8 | 6.9 | 7.8 | - | 12.3 | 14.1 | 16.0 | 18.4 | 20.2 | 20.2 | - | 8.8 | 10.0 | 19.3 | - | 23.4 | 24.6 | 23.6 | - | 19.8 | 19.0 | 16.9 | - | 7.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
5.8 | 5.2 | - | 16.5 | 14.9 | 16.5 | - | 16.7 | 14.7 | 12.8 | 10.5 | 13.8 | 16.8 | - | 6.8 | 9.4 | 24.4 | - | 13.6 | 16.1 | 16.1 | - | 12.6 | 12.1 | 17.0 | - | 15.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 92.7 | - | 95.3 | 87.7 | 106.0 | - | 135.9 | 128.0 | 113.7 | 88.5 | 96.4 | 101.7 | - | 38.9 | 43.4 | 89.3 | - | 78.7 | 80.1 | 89.4 | - | 85.9 | 79.3 | 83.2 | - | 50.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 87.6 | - | 78.8 | 72.8 | 89.5 | - | 119.1 | 113.4 | 100.9 | 78.0 | 82.6 | 84.8 | - | 32.1 | 34.0 | 64.9 | - | 65.1 | 64.0 | 73.3 | - | 73.3 | 67.2 | 66.2 | - | 34.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company American Well Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Evolent Health
EVH
|
$ 4.57 | 2.63 % | $ 522 M |  USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 35.39 | 0.07 % | $ 1.63 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 8.5 | 0.11 % | $ 158 M | USA |
 |
Phreesia
PHR
|
$ 10.94 | 0.18 % | $ 654 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.73 | 0.28 % | $ 121 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.36 | 3.7 % | $ 1.2 B | USA |
 |
So-Young International
SY
|
$ 2.27 | 3.52 % | $ 177 M |  China |
 |
Veeva Systems
VEEV
|
$ 310.36 | 0.2 % | $ 50.8 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.31 | 0.72 % | $ 4.48 M | China |
 |
HealthEquity
HQY
|
$ 92.03 | 0.25 % | $ 7.93 B | USA |
 |
Teladoc Health
TDOC
|
$ 5.67 | 2.75 % | $ 999 M | USA |
 |
Schrödinger
SDGR
|
$ 22.6 | 1.72 % | $ 1.66 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.13 | 0.3 % | $ 994 M | USA |
 |
Progyny
PGNY
|
$ 26.86 | 0.16 % | $ 2.29 B | USA |
 |
10x Genomics
TXG
|
$ 69.86 | 0.12 % | $ 8.72 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |